TY - JOUR
T1 - Risk of malignant outcome in patients with wolff-parkinson-white syndrome: results of 28-years prospective electrophysiological follow-up study
AU - Venuti, Angela
AU - Brisinda, Donatella
AU - Sorbo, Ar
AU - Iantorno, E
AU - Efremov, K
AU - Cataldi, C
AU - Fenici, Riccardo
PY - 2014
Y1 - 2014
N2 - Purpose: The Wolff-Parkinson-White (WPW) syndrome can be associated with
sudden death (SD), thus risk assessment (RA) with electrophysiological (EP) testing (EPT) is a mandatory to identify patients (pts) requiring catheter ablation (CA).
Our prospective study aimed to identify and treat WPW pts at high arrhythmogenic
risk (HAR), and to evaluate the predictive value of transesophageal EPT
(TEEPT) for RA, evaluation of treatment efficacy, and longitudinal EP follow up
(F-up) of untreated athletes/pts.
Methods: 318 WPW pts referred to us between 1985 and 2013. Antegrade effective refractory period (ERP) of accessory pathway (AP) and of the atrioventricular node (AVN), Wenckebach point (WP), shortest preexcited RR intervals (SPERRI) during atrial fibrillation (AF) and/or atrial pacing, and inducibility of supraventricular
arrhythmias (SVTA) were assessed, at rest (in supine and upright position)
and during effort.
Results: Out of 318 pts, 275 untreated pts (53.8% athletes) were enrolled.
AP’s/AVN’s ERP and SPERRIs varied as a function of autonomic modulation
and were shorter in the 128 symptomatic (S) compared with 147 asymptomatic
(AS) pts, (p<0.05). One or more sustained SVTA were inducible in 128/275 pts (46.54%), and AF in 70 pts. During the F-up (12.3±5.2 pts years), out of 57 pts classified at HAR, 37 were ablated. Before CA availability, two S pts, with inducible antidromic AVRT and AF (SPERRI <180 msec at rest), refused surgery and died suddenly (at rest). Both had self-discontinued antiarrhythmic therapy (AAD). Other 18 HAR pts were treated with AAD, without complications. Overall mortality was (0.06%/year of F-up). Among 218 pts classified at low (198) or medium (20) risk, 21 pts underwent elective CA for fit-for-duty requirements. Periodical
reevaluation was performed, if clinically or legally required (overall 922 F-up TEEPTs). 56 refused a second study (TEEPT2), which was performed in 161 pts. Compared to TEEPT1, EP data of untreated pts who underwent TEEPT2 were
highly reproducible. Clinical F-up data of untreated pts remained unchanged in
79.4%. Only 5.3% of initially AS became S, whereas 41.8% of S became AS.
Conclusions: This study confirms good long-term prognosis in WPW pts. Our
two casualties were avoidable, given the correct HAR identification provided by TEEPT, if surgery was accepted or CA available. No other patient had complications during the F-up, even though 72.2% of athletes were allowed to continue competitive sports activity. TEEPT is an efficient method which can minimize invasivity
for EP RA of WPW pts and for longitudinal F-up of professional athletes.
AB - Purpose: The Wolff-Parkinson-White (WPW) syndrome can be associated with
sudden death (SD), thus risk assessment (RA) with electrophysiological (EP) testing (EPT) is a mandatory to identify patients (pts) requiring catheter ablation (CA).
Our prospective study aimed to identify and treat WPW pts at high arrhythmogenic
risk (HAR), and to evaluate the predictive value of transesophageal EPT
(TEEPT) for RA, evaluation of treatment efficacy, and longitudinal EP follow up
(F-up) of untreated athletes/pts.
Methods: 318 WPW pts referred to us between 1985 and 2013. Antegrade effective refractory period (ERP) of accessory pathway (AP) and of the atrioventricular node (AVN), Wenckebach point (WP), shortest preexcited RR intervals (SPERRI) during atrial fibrillation (AF) and/or atrial pacing, and inducibility of supraventricular
arrhythmias (SVTA) were assessed, at rest (in supine and upright position)
and during effort.
Results: Out of 318 pts, 275 untreated pts (53.8% athletes) were enrolled.
AP’s/AVN’s ERP and SPERRIs varied as a function of autonomic modulation
and were shorter in the 128 symptomatic (S) compared with 147 asymptomatic
(AS) pts, (p<0.05). One or more sustained SVTA were inducible in 128/275 pts (46.54%), and AF in 70 pts. During the F-up (12.3±5.2 pts years), out of 57 pts classified at HAR, 37 were ablated. Before CA availability, two S pts, with inducible antidromic AVRT and AF (SPERRI <180 msec at rest), refused surgery and died suddenly (at rest). Both had self-discontinued antiarrhythmic therapy (AAD). Other 18 HAR pts were treated with AAD, without complications. Overall mortality was (0.06%/year of F-up). Among 218 pts classified at low (198) or medium (20) risk, 21 pts underwent elective CA for fit-for-duty requirements. Periodical
reevaluation was performed, if clinically or legally required (overall 922 F-up TEEPTs). 56 refused a second study (TEEPT2), which was performed in 161 pts. Compared to TEEPT1, EP data of untreated pts who underwent TEEPT2 were
highly reproducible. Clinical F-up data of untreated pts remained unchanged in
79.4%. Only 5.3% of initially AS became S, whereas 41.8% of S became AS.
Conclusions: This study confirms good long-term prognosis in WPW pts. Our
two casualties were avoidable, given the correct HAR identification provided by TEEPT, if surgery was accepted or CA available. No other patient had complications during the F-up, even though 72.2% of athletes were allowed to continue competitive sports activity. TEEPT is an efficient method which can minimize invasivity
for EP RA of WPW pts and for longitudinal F-up of professional athletes.
KW - Electrphysiologic study
KW - Sudden death
KW - Transesophageal pacing
KW - Wolff-Parkinson-White Syndrome
KW - Electrphysiologic study
KW - Sudden death
KW - Transesophageal pacing
KW - Wolff-Parkinson-White Syndrome
UR - http://hdl.handle.net/10807/61528
M3 - Article
SN - 1522-9645
VL - 35
SP - 529
EP - 529
JO - European Heart Journal
JF - European Heart Journal
ER -